We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Patients are 266 percent more likely to not pick up brand-name medications after requesting them at a pharmacy, compared to generic prescriptions, according to the Association for Accessible Medicine’s annual report. Read More
A new class-action lawsuit from a terminal blood cancer patient claims that Celgene abused consumer safety regulations to monopolize cancer drugs. Read More
A federal jury awarded GlaxoSmithKline $235 million in a suit against Teva, saying the generics manufacturer infringed on GSK’s patent for the cardiovascular drug Coreg when Teva marketed its generic for chronic heart failure as well as high blood pressure. Read More
Two-thirds of the way through fiscal year 2017, the FDA has received at least 877 ANDAs, passing fiscal 2016’s total of 852 and beating fiscal 2015’s total by more than 330 applications. Read More
The World Health Organization published its biennial update to its list of essential medicines, adding therapies for hepatitis C, HIV and leukemia, as well as new advice on combating antimicrobial drug resistance. Read More
The PTO’s Patent Trial and Appeal Board said it will review patents covering the blockbuster erectile dysfunction drug Cialis and a widely used pneumonia vaccine, Prevnar 13, granting petitions from Mylan and Merck Sharp & Dohme Corp. Read More
The PTO invalidated two more AbbVie patents on dosing regimens for Humira after continuing challenges from Coherus, which plans to submit its biosimilar version of the blockbuster drug for FDA approval later this year. Read More
The Congressional Budget Office officially scored the Senate bill reauthorizing the FDA’s user fee agreements, saying it would add $740 million to the budget and a negligible amount to the deficit over its five-year life. Read More